it (development name NBI-98854) has been used in trials studying the treatment and basic science of Tourette Syndrome and Tardive Dyskinesia. In April, 2017, it was approved by the FDA (as it) as the first and only approved treatment for adults with Tardive Dyskinesia (TD). 
